NewsRoom Articles - Page 29 of 46

WednesdayJan 18, 2023 9:00 am

Vision Energy Corp. (VENG) Announces Incorporation of New Dutch Subsidiaries to Accommodate Strategic Initiatives for Prospective Partners

Vision Energy has announced the incorporation of Vision Hydrogen BV as a project development company for its planned Ammonia Cracking Facility for back-cracking imported green ammonia into hydrogen gas as a service On December 2, 2022, Vision entered a Memorandum of Understanding with Linde Engineering with a mutual interest to participate in co-investment, development, and operations associated with hydrogen production through ammonia back-cracking Vision Energy has also incorporated “Evolution Terminals Operating BV,” a dedicated entity that will jointly own and operate logistics infrastructure The company’s Green Energy Hub is positioned to be the first terminal in Europe focused on green…

ThursdayJan 12, 2023 11:15 am

Vision Energy Corp. (VENG) Files Application Initiating Formal Environmental Permit Assessment Process for Green Energy Hub Terminal Development Project in the Netherlands

Vision Energy is pioneering a Green Energy Hub terminal development project for the importation, storage, handling, and distribution of low-carbon renewable fuels and hydrogen carriers, including green ammonia, methanol, and biofuels The company intends to construct the development in phases, with Phase 1 accommodating 400,000 cubic meters of renewable liquid bulk storage and supporting infrastructure Vision Energy has engaged environmental experts and specialist Netherlands-based consultancy firms to undertake detailed studies to support final permit applications for the development Vision Energy (OTCQB: VENG), through its wholly owned subsidiary Evolution Terminals BV, is in the advanced stages of planning the construction of…

WednesdayJan 11, 2023 9:45 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Adds to its Existing Suite of Global Patents with First Granted Patent in Canada

Lexaria has announced patent #3,093,414, its first patent in Canada, its 28th granted patent worldwide, and the first patent from its sixth patent family This patent joins the ranks of previously issued patents in Australia, India, Japan, and the EU, even as similar patent applications for skin-based delivery of patented DehydraTECH formulations remain pending in many countries In Lexaria’s 2018 study, DehydraTECH-processed CBD demonstrated almost a 1,900% increase in CBD permeability through human skin compared to a control formulation that was devoid of any commercial penetration enhancers This patent inches Lexaria closer to taking advantage of the cosmeceuticals market, projected…

TuesdayJan 10, 2023 12:00 pm

Aditxt, Inc. (NASDAQ: ADTX) Bolsters Goal to Conduct First-In-Human Clinical Trial Evaluating ADI(TM) Tech with Formation of Adimune, Inc. Subsidiary; Appoints Industry Veteran as Subsidiary Chairman and CEO

Aditxt recently announced the formation of a U.S.-based wholly owned subsidiary, Adimune, Inc., and appointed Joachim-Friedrich Kapp, M.D., Ph.D., a 30-year veteran of the pharmaceutical industry, as its Chairman and CEO Dr. Kapp will be tasked with leading and developing the Apoptotic DNA Immunotherapy(TM) (“ADI(TM)”) technology toward clinical trials Aditxt also plans to submit a Clinical Trial Application (“CTA”) for immunotherapeutic technology drug candidate ADI(TM)-100, seeking approval for Adimune(TM) to conduct the first-in-human study in psoriasis patients, beginning in the second half of 2023 ADI(TM) is a nucleic acid-based technology platform that utilizes a novel antigen-specific approach to induce immune…

MondayJan 09, 2023 9:45 am

Vision Energy Corp. (VENG) Subsidiary Pioneering a Green Energy Hub in the North Sea Port of Vlissingen, The Netherlands

A total of 194 parties (including the European Union) have joined the Paris Agreement intending to reach carbon-neutral status by 2050 to reduce the impact of global climate change Vision Energy’s Green Energy Hub in the Netherlands will help with import, storage, and distribution of low-carbon renewable fuels and hydrogen carriers The company plans for first operations to commence in 2026, with the terminal running 24 hours a day, 365 days a year Climate change is a global emergency with negative impacts beyond national borders – requiring cooperation and collaborative solutions amongst nations and world leaders. The Paris Agreement is…

FridayJan 06, 2023 11:15 am

Flora Growth Corp. (NASDAQ: FLGC) Acquisition of Franchise Global Health Completed, Rapid Jump in Potential for European Cannabis Sales

International cannabis operator Flora Growth Corp. is rapidly expanding its global footprint and Colombia-based international supply chain thanks to strategic acquisitions during the past several months Flora’s most recent acquisition was concluded just before Christmas on finalization of an agreement with multi-national operator Franchise Global Health Inc. that strengthens Flora’s position in Europe Franchise Global Health (“FGH”) serves 1,200 pharmacies in Germany, which the companies regard as the doorway to the rest of Europe, and it also has a footprint in Portugal and Denmark, while Flora Growth has completed exports to Switzerland and the Czech Republic Flora reported a 604…

ThursdayJan 05, 2023 9:00 am

Vision Energy Corp. (VENG) Expands Project Management and Development Team, Advancing Green Energy Hub Project in North Sea Port of Vlissingen

Through their ETBV project in Europe, renewable energy developer Vision Energy is continuing its work to realize project development objectives and has increased its core team of commercial and engineering professionals for its Green Energy Hub project The company’s Project Management and Consultancy (“PMC”) team, with decades of experience working with major industry operators, has collectively developed over 8 million cubic meters of bulk storage capacity worldwide The Green Energy Hub project is strategically located in the North Sea port of Vlissingen at the mouth of the Westerschelde estuary in the Netherlands, and is positioned to be the first terminal…

TuesdayJan 03, 2023 9:45 am

Vision Energy Corp. (VENG) Update Underscores Acceleration of its Green Energy Hub Development Near European Hydrogen Backbone

Vision Energy Corporation is a developer dedicated to carbon-reduction assets, currently focused on establishment of a Green Energy Hub serving as Northwestern Europe’s first import, storage and handling terminal for hydrogen and other renewable energy products The Green Energy Terminal site in the Netherlands’ North Sea Port of Vlissingen is strategically located near developing transnational European Hydrogen Backbone infrastructure to help reduce Europe’s dependence on Russian fossil fuels Vision Energy’s wholly owned subsidiary Evolution Terminals BV is spearheading the terminal development, and the company recently provided an update of its timeline that shows construction permit applications are expected to be…

WednesdayDec 28, 2022 11:15 am

Aditxt Inc. (NASDAQ: ADTX) Announces Goal of First-in-Human Trials for Drug Candidate ADI(TM)-100 with a Focus on Psoriasis

Dr. Joachim-Friedrich Kapp is leading Aditxt’s ADI(TM) immune modulation technology development toward clinical trialsThe global psoriasis therapeutics market was valued at $22.9 billion in 2021 and is projected to reach $55.8 billion by 2031, growing at a CAGR of 9.3%The primary goal of the first-in-human clinical trial is to demonstrate the safety of Aditxt’s ADI(TM) technology; in addition, the trial has been designed to evaluate the ability of ADI(TM) to restore immune tolerance Aditxt (NASDAQ: ADTX), a biotech innovation company developing and commercializing technologies with a focus on monitoring and modulating the immune system, is focused on mapping and reprogramming…

WednesdayDec 28, 2022 9:45 am

CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Continues to See Growth in Patient Enrollment for Brain Cancer Drug Candidate Global Clinical Trial

CNS Pharmaceuticals is conducting a potentially pivotal clinical trial in the United States and Europe to establish the effectiveness of a drug candidate for combating incurable glioblastoma (“GBM”) brain cancersCNS’s flagship drug candidate is called Berubicin, a product initially developed by another company with encouraging small-population results in 2006, and CNS is expanding the testing with expectations of eventually delivering an innovative new GBM treatment to marketThe company aims to enroll more than 200 patients in its global Berubicin trial on a 2:1 randomization schema comparing Berubicin-treated patients to those receiving second-line standard of care chemotherapy agent lomustineThe company recently…

Spotlighting undiscovered companies with enormous upside potential.

Contact us: (512) 354-7000